Predicting long-term injection results for high myopia eye disease
Part of Eyes & vision clinical trials.
This study uses detailed eye scans (OCT and OCTA) to predict how well anti-VEGF injections will work in the long run for people with high myopia and an eye condition called myopic choroidal neovascularization (abnormal blood vessel growth caused by myopia). If you fit the criteria, participating could help doctors know if these injections are a good option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high myopia (needing glasses stronger than -6.00 or your eye length is longer than 26.5 mm).
- You have been diagnosed with a type of abnormal blood vessel growth in the back of the eye that is caused by myopia.
- The abnormal blood vessel is active (leaking or growing) and you have not yet had any treatment for it.
- You have not had any eye surgery in the past (like vitrectomy).
- Your eye imaging scans (OCT and OCT angiography) are clear enough to be read by specialists.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the treatment experience for people with severe nearsightedness who develop abnormal blood vessels under the retina, which can cause vision loss. It aims to understand how much treatment is needed and what patients go through.
This study uses a special eye scanner (OCTA) to look at the choroid, a layer of blood vessels behind the retina, in people with high myopia. It will help doctors understand how high myopia affects this part of the eye and may guide future care.
This study tests a new medication, OCUL101, given as an injection into the eye, to see if it is safe and effective for people with a certain type of wet age-related macular degeneration (AMD). The trial compares OCUL101 with another standard treatment, looking at how well it works and how long it lasts over 96 weeks.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests a combination of two treatments—a heat procedure and a medication injection—to reduce abnormal blood vessel growth on the clear front surface of your eye (cornea). The goal is to improve your vision and prevent further damage.
This study looks at how the eyes of people with diabetes-related swelling in the retina change after their very first anti-VEGF injection. By measuring early changes in OCT scans, doctors hope to learn more about how well the treatment works and how to predict outcomes.
Hear when a new Myopic Choroidal Neovascularization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.